BEVERLY-2 was a phase 2 study in patients with primary HER2+ IBC (ClinicalTrials.gov Identifier: NCT00717405; An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy; Table 1) [113]. Here, ERBB2 is linked to breast carcinoma.